The Departments of Pathology, Neurosurgery and Gynecology/Obstetrics and the Kimmel Cancer Center at Johns Hopkins have received almost $8 million for new research projects to discover cures for a number of fatal cancers, including ovarian cancer, pancreatic cancer and glioblastoma. The projects are being financed by Break Through Cancer, a cancer research foundation, as part of an effort for researchers across a quintet of cancer research centers.
The other cancer research centers include the University of Texas MD Anderson Cancer Center in Houston; Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts; the Memorial Sloan Kettering Cancer Center in New York; and Dana-Farber Cancer Institute in Boston.
William Nelson, chair of the Break Through Cancer board, stated that funding these new research avenues would allow researchers to discover new management or treatment approaches for a range of fatal cancers. Nelson is also director of the Johns Hopkins Kimmel Cancer Center.
One of the projects to be funded will look into how to obstruct ovarian cancer before it develops. Le-Ming Shih, director of the TeLinde Gynecologic Pathology Lab, explained that most severe high-grade ovarian cancers originated from the fallopian tubes. Findings from a recent study show that the removal of fallopian tubes could significantly reduce the risk of developing ovarian cancer. Scientists will also try developing noninvasive methods of imaging to streamline the harvesting of cancerous lesions in the fallopian tubes.
In addition to this, the funding awarded will be used to develop new ways for targeting and understanding minimal residual disease, which usually leads to the recurrence of cancer. Minimal residual disease isn’t easily detectable using current methods and is managed using maintenance therapies that try to hinder the reappearance of cancer.
This research will be led by Stephanie Gaillard, director of early-phase clinical trials in gynecologic cancer; Elana Fertig, director of quantitative sciences at the Division and Associate Cancer Center; and Christopher Vanden Bussche, codirector of the Convergence Institute.
The funding will also be used to discover why tumor cells develop resistance against KRAS inhibition. KRAS are mutations in a gene that drive the development of pancreatic ductal adenocarcinoma. The researchers’ objective is to develop better treatments that target mutant KRAS forms in pancreatic cancer through clinical trials and preclinical studies.
The researchers who will be involved in this project include associate director of the Quantitative Sciences Division Hao Wang; Elana Fertig; clinical research nurse manager Katrina Purtell; Elizabeth Thompson; Jacquelyn Zimmerman; and the codirector of Cancer Genetics and Epigenetics Nilo Azad.
For-profit companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also conducting their own cancer research, and all these efforts increase the odds that meaningful breakthroughs could soon be made in cancer diagnosis and care.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Doctors in Spain recently handled a fascinating yet terrifying case of a patient that developed brain cancer-like symptoms and…
While immunotherapy is revolutionizing cancer therapy, response rates to these novel treatments are low and some patients…
Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production…
The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage…
As July came to an end, the United States reached an undesirable milestone: exceeding the…
Scientists and public health experts are warning that climate change is accelerating the rate at which infectious…